Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status.

导出 LinkOut

翻译打印收藏纠错

第一作者： Manoj,Gupta

第一单位： 1Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.

作者： Manoj,Gupta ^[1] ; Partha Sarathi,Choudhury ^[1] ; Sudhir,Rawal ^[2] ; G,Karthikeyan ^[3] ; Vineet,Talwar ^[4] ; Kumar Deep,Dutta ^[4] ; Amitabh,Singh ^[2]

作者单位： 1Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. ^[1] 2Department of Uro - Gynae Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. ^[2] 3Amity Institute of Virology and Immunology, Amity University, Noida, Uttar Pradesh India. ^[3] 4Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. ^[4]

关键词 Low performance status Lu-177-PSMA Metastatic castration resistant prostate cancer Safety and efficacy

DOI 10.1007/s13139-019-00624-8

PMID 31867078

发布时间 2022-04-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交